Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate positive sentiment, driven by raised revenue guidance, strong growth in TissueCypher and DecisionDx-Melanoma tests, and optimistic future cash flow expectations. Despite some uncertainties in FDA submission timelines and reimbursement pathways, the overall outlook is upbeat. The company's strategic initiatives and growth potential in the GI space further bolster confidence. The market is likely to react positively, with stock price expected to rise by 2% to 8% over the next two weeks.
Key Financial Performance
Revenue $86.2 million, a decrease of $0.8 million or 1% year-over-year. The decrease was due to a $12.5 million drop in revenue from dermatological tests, offset by an $11.7 million increase in revenue from non-dermatological tests.
Gross Margin 77.3%, down from 80.7% year-over-year. Adjusted gross margin was 79.5%, down from 83.2%. The decline was attributed to higher personnel costs, lab services, and lab supplies expenses.
Net Income $4.5 million, down from $8.9 million year-over-year. The decrease was due to higher operating expenses, including personnel costs and inflationary wage adjustments.
Adjusted EBITDA $10.4 million, down from $21.5 million year-over-year. The decline was due to increased operating expenses and lower gross margins.
Cash, Cash Equivalents, and Marketable Securities $275.9 million, reflecting a strong balance sheet to support growth initiatives.
Test Report Volume 26,574 tests, with core revenue drivers growing 33% year-over-year. DecisionDx-Melanoma tests increased 4% year-over-year, and TissueCypher tests grew 92% year-over-year.
Operating Expenses $90.4 million, up from $82 million year-over-year. The increase was driven by higher sales and marketing expenses, general and administrative expenses, and cost of sales.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
DecisionDx-Melanoma: Delivered 9,981 test reports in Q2 2025, a 16% sequential increase from Q1 2025 and a 4% year-over-year increase from Q2 2024. Associated with a 32% reduction in mortality risk compared to untested patients.
DecisionDx-SCC: Delivered 4,762 test reports in Q2 2025. Reimbursement challenges due to noncoverage policy effective April 24, 2025. Reconsideration request submitted to Novitas and MolDx.
TissueCypher: Delivered 9,170 test reports in Q2 2025, a 92% year-over-year growth from Q2 2024. Growth driven by unmet clinical need and commercial optimization.
Atopic Dermatitis Diagnostic Test: Collaboration with SciBase to develop a diagnostic test for predicting flares in atopic dermatitis patients. Internally developed pipeline test validated to predict treatment responses for moderate to severe atopic dermatitis. Expected launch by end of 2025.
Revenue Guidance: Raised 2025 revenue guidance to $310-$320 million, up from $287-$297 million. Normalized revenue growth excluding DecisionDx-SCC is estimated at 21%-26%.
Previse Acquisition: Acquisition aims to enhance gastrointestinal offerings, including multi-omics approach for Barrett's esophagus and non-endoscopic sample collection device.
Financial Performance: Q2 2025 revenue of $86.2 million, a 1% decrease year-over-year. Dermatological test revenue decreased by $12.5 million, while non-dermatological test revenue increased by $11.7 million. Gross margin at 77.3%.
Cash Position: Ended Q2 2025 with $275.9 million in cash, cash equivalents, and marketable securities. Positive net cash flow from operations expected for 2025.
M&A Strategy: Focused on complementing existing portfolio, diversifying test portfolio and payer mix, and ensuring transactions support profitable growth.
SciBase Collaboration: Collaboration to develop diagnostic tests for atopic dermatitis using advanced EIS technology.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
DecisionDx-SCC Test Reimbursement: The Novitas Local Coverage Determination policy, effective April 24, 2025, included noncoverage language for the DecisionDx-SCC test. This has led to a significant decrease in revenue from dermatological tests, specifically impacting DecisionDx-SCC, which saw a $12.5 million revenue drop. The company has submitted a reconsideration request, but there is no specified timeline for a final decision, creating uncertainty.
Gross Margin Decline: Gross margin decreased from 80.7% in Q2 2024 to 77.3% in Q2 2025. Adjusted gross margin also declined from 83.2% to 79.5%. This decline is attributed to higher personnel costs, lab services, and lab supplies, reflecting increased test report volumes and inflationary wage adjustments.
Increased Operating Expenses: Operating expenses rose to $90.4 million in Q2 2025 from $82 million in Q2 2024. This increase is driven by higher sales and marketing expenses, general and administrative costs, and cost of sales, primarily due to headcount expansion, inflationary wage adjustments, and increased business development activities.
Regulatory and Reimbursement Risks: The company faces challenges in the dynamic reimbursement environment, particularly with the noncoverage decision for DecisionDx-SCC. This creates risks for revenue stability and growth, as well as potential delays in achieving reimbursement for new tests.
Pipeline and M&A Execution Risks: The company is investing in pipeline initiatives and M&A activities, such as the SciBase collaboration and Previse acquisition. However, these initiatives carry execution risks, including the potential for delays, unsuccessful validation, or failure to achieve expected returns.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2025: Castle Biosciences has raised its total revenue guidance for 2025 to a range of $310 million to $320 million, up from the previously provided range of $287 million to $297 million. This reflects adjustments for the DecisionDx-SCC LCD effective April 24, 2025. Excluding DecisionDx-SCC revenue, normalized revenue growth for 2025 is expected to be approximately 21% to 26%.
DecisionDx-Melanoma Volume Growth: The company expects high single-digit volume growth for DecisionDx-Melanoma for the full year 2025 compared to 2024.
TissueCypher Growth Drivers: Castle Biosciences anticipates continued strong growth for TissueCypher, driven by recognition of unmet clinical needs and commercial optimization efforts, including education and awareness.
Pipeline Test for Atopic Dermatitis: The company plans to launch a new pipeline test for atopic dermatitis by the end of 2025, which aims to predict treatment responses for patients eligible for systemic therapy.
Collaboration with SciBase: Castle Biosciences has entered into a collaboration with SciBase to develop a diagnostic test for predicting flares in atopic dermatitis patients, targeting a U.S. market of up to 24 million people.
Previse Acquisition and GI Offerings: The Previse acquisition is expected to enhance the company's gastrointestinal offerings, including a multi-omics approach for Barrett's esophagus and a non-endoscopic sample collection device for GI diseases.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:With the breakthrough designation for Dx-Melanoma, what are the plans for FDA approval studies?
A:Castle Biosciences is pushing forward towards an FDA submission for Dx-Melanoma following its breakthrough designation. However, the timing of the submission has not been made public.
Q:Are you getting paid on any volume that isn't Medicare for SCC?
A:Castle Biosciences receives episodic payments on commercial claims for SCC, but these payments are not significant percentages and are inconsistent.
Q:How many GI reps have reached average productivity levels?
A:The GI sales team scaled to current territory levels by year-end, with training in Q1. By Q3 and Q4, the team is expected to reach full productivity.
Q:What are the utilization trends for the derm sales force refocused on melanoma?
A:Data on utilization trends is not available yet. The shift in focus occurred late in Q2, and future modeling will provide insights in Q3 and Q4.
Q:What is the reimbursement outlook for the atopic dermatitis product launching by year-end 2025?
A:Castle Biosciences is pursuing 3-4 reimbursement pathways for the atopic dermatitis product but has not disclosed details. Revenue impact is expected to be immaterial for 2026, with growth anticipated in 2027-2029.
Q:Will Castle continue offering the SCC test despite the noncoverage decision?
A:Yes, Castle will continue offering the SCC test, even with volume expected to moderate. The company believes it is the right decision for patient care and is pursuing reconsideration requests with Novitas and MolDX.
Q:What are the drivers for the raised revenue guidance for the year?
A:The raised guidance reflects strong business drivers, with seasonal flatness expected from Q2 to Q3 and Q3 to Q4 for melanoma.
Q:What is the expected cadence of TissueCypher volume growth?
A:Castle expects continued growth in TissueCypher volumes, with no seasonality observed yet due to underpenetration.
Q:What is the status of the reconsideration request for SCC with MolDX?
A:Castle submitted a reconsideration request to MolDX in April and expects a response by Labor Day. The submission includes 8-9 new peer-reviewed publications addressing prior concerns.
Q:What are the gross margin expectations for the rest of the year?
A:Adjusted gross margins are expected to be in the low to mid-70s for Q4, slightly lower than Q2 due to the roll-off of SCC reimbursement.
Q:What is the cash flow outlook for 2026?
A:Castle has not provided specific guidance for 2026 cash flow but expects positive trends driven by TissueCypher growth and melanoma rebound.
Q:Is there cross-selling between GI tests and TissueCypher?
A:Currently, there is no cross-selling, but Castle sees potential for combining spatialomics with genomics to create more accurate tests.
Q:Will further studies be needed for FDA approval of DecisionDx-Melanoma?
A:Castle does not believe further studies are needed for FDA approval, as existing data is expected to support the process.
Q:How are internal resources being prioritized among various initiatives?
A:Resources are being allocated to integrate multi-omics approaches for TissueCypher, develop capsule sponge technology, and advance atopic dermatitis tests, with minimal additional resource requirements.
Q:Will TissueCypher's growth impact margins this year?
A:TissueCypher's lower gross margin may slightly dilute overall margins, but improvements in cost structure have been made.
Q:What is the expected growth rate for DecisionDx-Melanoma in the back half of the year?
A:High single-digit growth is expected for the full year, with no specific guidance for next year yet.
Q:What is driving TissueCypher growth: new clinicians or existing ones?
A:Both new clinician adoption and increased penetration among existing users are contributing to growth, with early-stage penetration still ongoing.
Q:What progress is being made with private payers for DecisionDx-Melanoma?
A:Progress with private payers is slow due to resistance, despite strong data and widespread physician adoption.
Q:Are there opportunities for collaboration with SciBase on melanoma?
A:The current collaboration focuses on atopic dermatitis, but future opportunities for melanoma collaboration with SciBase may be evaluated.
Q:Review of Unclear Management Responses
A:Management avoided providing specific timelines for FDA submission for Dx-Melanoma, details on reimbursement pathways for the atopic dermatitis product, and insights into utilization trends for the derm sales force refocused on melanoma. Additionally, they did not disclose the exact contents of the SCC reconsideration request or provide specific guidance for 2026 cash flow and DecisionDx-Melanoma growth next year.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CMS guideline
DecisionDx Melanoma
DecisionDx SCC
LLC Research
Markets
NCI SEER
Novitas
Previse
Research Division
SEER study
TissueCypher
agreement SciBase
apple
area
atopic dermatitis
clinician DecisionDx
cohort patient
collaboration
collection
date service
decrease test
development program
expression
flare
index
initiation
lab supply
license agreement
optimization
portfolio
reconsideration request
request notification
service lab
signature
test DecisionDx
test increase
use DecisionDx
CSTL Transcript
Castle Biosciences, Inc. (CSTL) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call highlights strong financial performance with a 25% revenue increase, improved gross margin, and a shift from net loss to net income. Although operating expenses rose, they were due to strategic investments. The guidance for 2026 indicates continued growth, and cash flow improvements further reinforce a positive outlook. Despite inherent risks in forward-looking statements, the overall sentiment is positive, suggesting a likely stock price increase in the short term.
Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call highlights increased operating expenses and a net loss for 2025, contrasting with a previous net income. Adjusted EBITDA has significantly decreased, and there is uncertainty around FDA approval and NCCN guideline inclusion for key products. Despite strong market opportunities and revenue guidance, these financial concerns and vague management responses suggest a negative market reaction.
Castle Biosciences, Inc. (CSTL) Q3 2025 Earnings Call Transcript
Unknown11-3
The earnings call presents mixed signals: positive revenue growth and pipeline developments are countered by declining margins, increased expenses, and a net loss. The raised revenue guidance is a positive sign, but the lack of clarity on reimbursement pathways and flat SCC volumes temper enthusiasm. The Q&A reveals some analyst concerns, particularly regarding reimbursement and FDA approval impacts. The absence of a market cap limits prediction accuracy, but the overall sentiment leans towards neutral, given the balancing of positive growth prospects against financial pressures and uncertainties.
Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript
Positive8-4
The earnings call summary and Q&A indicate positive sentiment, driven by raised revenue guidance, strong growth in TissueCypher and DecisionDx-Melanoma tests, and optimistic future cash flow expectations. Despite some uncertainties in FDA submission timelines and reimbursement pathways, the overall outlook is upbeat. The company's strategic initiatives and growth potential in the GI space further bolster confidence. The market is likely to react positively, with stock price expected to rise by 2% to 8% over the next two weeks.
CSTL Slides
CSTL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
